1948-1990: Going global
The Boehringer Ingelheim history from 1948-1990, with milestones
Search
SIRPα Cancer Immunology Research
Boehringer Ingelheim scientists are investigating a new target in the innate immune system - signal-regulating protein alpha or SIRPα.
Three challenges shape future antiparasitic treatment
The three key challenges that will shape the future of antiparasitic treatment
Afrika Kommt! - The Ripple Effect
What the Afrika Kommt! Fellowship Program means to Boehringer Ingelheim
Camilla Krogh Lauritzen
Collaboration to fight NCDs
70 percent of global deaths are attributable to NCDs and severely impacting on people in low- and middle-income countries. Help is desperately needed.
Purevax®
Purevax® is the only fully adjuvant-free feline vaccine range.
Targeting Tumor Stroma
Boehringer Ingelheim’s research approach in stromal biology may lead to new medicines that will change the face of cancer and give new hope to patients
“Rapid progress towards clinical candidates”
Boehringer Ingelheim forms a joint venture to create the next generation of antimicrobials.
The Angels Initiative
10 things you should know about rabies
10 things you should know about rabies
COVID-19 Supply Chain and Production
COVID
Saving Stroke Patients around the world
Suffering a stroke is one of the most devastating medical emergencies that can happen to a person. Over 15 million people worldwide suffer a stroke every year.
COVID-19: Research Update
Boehringer Ingelheim stops treatment with experimental medication in study investigating benefits for severely ill patients with COVID-19
Code of Conduct
Our Code of Conduct sets the ethical standards that guides all our business activities. It´s about all of us. Each individual plays a vital role in bringing the Code of Conduct to live.
GPP Interview with Professor Barker
An interview with Prof. Barker about generalized pustular psoriasis, its burden on patients and how patient outcomes can be improved
Bees and biodiversity
At Boehringer Ingelheim we attach great importance to sustainable planting on our company site – and to protecting the bees.
Championing novel science
Dr. Vikas Mohan Sharma announces FDA fast-track designation for BI 1358894 as potential treatment for Borderline Personality Disorder.
Bites that matter
The Bluetongue virus (BTV) is a worldwide infectious viral disease from the Reoviridae family known for its impact on domestic and wild ruminants' health and the economic loss it represents on trade. It doesn't affect humans, but it is a threat to animals
It’s Your Heart. Protect It. The Podcast.
In season 2, we hear from a range of experts to explore further how the interconnected systems call for collaboration and approach to care.
A Deep Dive into Wet AMD
Wet AMD is a disease of the central portion of the retina (the macula) which is responsible for high visual acuity that allows for color vision, reading and facial recognition
sustainably fighting rabies info hub
Did you know that every nine minutes, rabies takes a human life? Find out how we support the elimination of this deadly disease.
Behind the Lab
Delve behind the lab to see how our Retinal Health scientists are spearheading research into novel therapeutics to treat retinopathies.
Rare Diseases: Rare but not alone
We are committed to listen and learn from patients with rare diseases to deliver breakthrough therapies.
Prevention of Schizophrenia
Can schizophrenia be prevented?That’s what investigators are hoping to find out, according to scientists attending the American College of Neuropsychopharmacology (ACNP) in Orlando, Florida.[node:body][node:title]